Oncotarget

Research Papers:

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

Dong Wang, Min Wang, Nan Jiang, Yuan Zhang, Xing Bian, Xiaoqing Wang, Thomas M. Roberts, Jean J. Zhao, Pixu Liu and Hailing Cheng _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:13153-13166. https://doi.org/10.18632/oncotarget.7549

Metrics: PDF 3312 views  |   HTML 3403 views  |   ?  


Abstract

Dong Wang1,2, Min Wang1, Nan Jiang1, Yuan Zhang1, Xing Bian1, Xiaoqing Wang1, Thomas M. Roberts3,4, Jean J. Zhao3,4, Pixu Liu1, Hailing Cheng1

1Cancer Institute, The Second Hospital of Dalian Medical University, Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China

2Department of Histology and Embryology, Binzhou Medical College, Yantai 264000, China

3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA

4Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA

Correspondence to:

Hailing Cheng, e-mail: hailingcheng_dmu@163.com

Pixu Liu, e-mail: pixu_liu@dmu.edu.cn

Jean J. Zhao, e-mail: jean_zhao@dfci.harvard.edu

Keywords: ovarian cancer, BKM120, Olaparib, BRCA, combination therapy

Received: October 02, 2015     Accepted: January 23, 2016     Published: February 21, 2016

ABSTRACT

Recent preclinical studies revealed the efficacy of combined use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib in breast and prostate cancers. The current study investigated the effect of such drug combination on ovarian cancer. Here we showed that combined inhibition of PI3K and PARP effectively synergized to inhibit proliferation, survival and invasion in the majority of ovarian cancer cell lines harboring PIK3CA mutations, including SKOV3, HEYA8, and IGROV1. Mechanistically, combined treatment of PARP and PI3K inhibitors resulted in an exacerbated DNA damage response and more substantially reduced AKT/mTOR signaling when compared to single-agent. Notably, ovarian cancer cells responsive to the PI3K/PARP combination displayed decreased BRCA1/2 expression upon drug treatment. Furthermore, the effect of the drug combination was corroborated in an intraperitoneal dissemination xenograft mouse model in which SKOV3 ovarian cancer cells responded with significantly decreased BRCA1 expression, suppressed PI3K/AKT signaling and reduced tumor burden. Collectively, our data suggested that combined inhibition of PI3K and PARP may be an effective therapeutic strategy for ovarian cancers with PIK3CA mutations and that the accompanied BRCA downregulation following PI3K inhibition could serve as a biomarker for the effective response to PARP inhibition.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7549